1013916-37-4

Basic information

• Product Name: 2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one
• Synonyms: 2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one;Pyrido[2,3-d]pyriMidin-7(8H)-one, 2-chloro-8-cyclopentyl-5-Methyl-;2-chloro-8-cyclopentyl-5-Me;Palbociclib Intermediate2;Palbociclib intermediates;2-Chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (For Palbociclib);2-chloro-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7-one;2-chloro-8-cyclopentyl-5-methyl-7H,8H-pyrido[2,3-d]pyrimidin-7-one
• CAS NO: 1013916-37-4
• Molecular Formula: C₁₃H₁₄ClN₃O
• Molecular Weight: 263.72276
• EINECS: 1592732-453-0
• Product Categories: Anticancer
• Mol File: 1013916-37-4.mol
• Article Data: 18

Chemical Properties

• Boiling Point: 428.0±34.0 °C(Predicted)
• Appearance: /
• Density: 1.346±0.06 g/cm3(Predicted)
• Storage Temp.: under inert gas (nitrogen or Argon) at 2-8°C
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 0.82±0.20(Predicted)
• Water Solubility: Slightly soluble in water.
• CAS DataBase Reference: 2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one(1013916-37-4)
• EPA Substance Registry System: 2-chloro-8-cyclopentyl-5-Methylpyrido[2,3-d]pyriMidin-7(8H)-one(1013916-37-4)

Safety Data

• Hazardous Substances Data: 1013916-37-4(Hazardous Substances Data)

Usage

Uses

2-Chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-d]pyrimidin-7-one is used as pharmaceutical intermediate.

Upstream product

• 733039-20-8 5-bromo-2-chloro-N-cyclopentylaminopyrimidine-4-amine 
• 18269-64-2 crotonic acid trimethylsilyl ester 
• 3724-65-0 2-butenoic acid 
• 1003-03-8 Cyclopentamine 
• 107-93-7 (E)-but-2-enoic acid 

Downstream Products

• 1016636-76-2 2-chloro-5-methyl-6-bromo-8-cyclopentylpyridine[2,3-d]pyrimidin-8-hydro-7-one 
• 571188-82-4 tert?butyl 4?(6?((6?bromo?8?cyclopentyl?5?methyl?7?oxo?7,8?dihydropyrido[2,3?d]pyrimidin?2?yl)amino)pyridin?3?yl)piperazine?1?carboxylate 
• 866084-31-3 tert?butyl 4?(6?((6?(1?butoxyvinyl)?8?cyclopentyl?5?methyl?7?oxo?7,8?dihydropyrido[2,3?d]pyrimidin?2?yl)amino)pyridin?3?yl)piperazine?1?carboxylate 
• 571190-30-2 PD 0332991 
• 1651214-74-2 4-[6-(6-acetyl-8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-ylamino)pyridine-3-yl]piperazine-1-carboxylic acid tert-butyl ester 
• 1415560-29-0 2,6-dibromo-8-cyclopentyl-5-methylpyrido[2,3-d]pyrimidin-7(8H)-one 
• 571189-65-6 4-[6-(8-cyclopentyl-5-methyl-7-oxo-7,8-dihydropyrido[2,3-d]pyrimidin-2-ylamino)pyridin-3-yl]piperazine-1-carboxylic acid tert-butyl ester 
• 362656-23-3 8?cyclopentyl?5?methyl?2?(methylthio)pyrido[2,3?d]pyrimidin?7(8H)?one 

Relevant articles and documents

Palbociclib Commercial Manufacturing Process Development. Part I: Control of Regioselectivity in a Grignard-Mediated SNAr Coupling

This is the first in a series of three papers describing commercial manufacturing process development for palbociclib (1). This manuscript focuses on the SNAr coupling between aminopyridine 3 and chloropyrimidine 7. The regioselectivity of the SNAr coupling was studied from a synthetic and mechanistic perspective. Grignard bases were identified as the preferred class of bases for this reaction, allowing for a simplified process and reduced usage factor for aminopyridine 3. The development of this SNAr reaction into a scalable commercial manufacturing process is also described.

Preparation method of CDK4/6 kinase inhibitor SHR6390

The invention relates to a preparation method of a CDK4/6 kinase inhibitor SHR6390. According to the preparation method disclosed by the invention, the SHR6390 can be rapidly and effectively prepared through six steps of chemical reactions. In the first step of reaction, the advantage of high reaction activity of the fourth site of pyrimidine is fully utilized, a target product compound 3 can be well obtained under mild conditions, in the fourth step of reaction, after-treatment of the synthesis reaction of a compound 8 is simple, a good white solid product can be obtained basically through filtration and washing, purification is not needed, and the method is suitable for amplification and process production.

Preparation method of palbociclib intermediate

The invention relates to the field of medicine synthesis, in particular to a preparation method of a palbociclib intermediate. According to the preparation method, a compound I, namely 2,4-dichloropyrimidine is used as an initial raw material, and is subjected to substitution by cyclopentylamine, amine ester exchange with methyl acetoacetate and catalytic cyclization by boron trifluoride diethyl ether so as to obtain a target compound IV, namely 2-chloro-8-cyclopentyl-5-methyl-8H-pyrido[2,3-D]pyrimidinyl-7-one. The synthesis route designed by the invention avoids the use of a palladium catalyst, has the advantages of mild overall reaction conditions, high reaction yield and low production cost, is suitable for industrial production, and is green and environment-friendly.